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CD44 is a facultative proteoglycan implicated in cell adhesion and trafficking, as well as in tumor survival
and progression. We demonstrate here that CD44 heparan sulfate proteoglycan (CD44HSPG) recruits
proteolytically active matrix metalloproteinase 7 (matrilysin, MMP-7) and heparin-binding epidermal growth
factor precursor (pro-HB-EGF) to form a complex on the surface of tumor cell lines, postpartum uterine and
lactating mammary gland epithelium, and uterine smooth muscle. The HB-EGF precursor within this complex
is processed by MMP-7, and the resulting mature HB-EGF engages and activates its receptor, ErbB4, leading
to, among other events, cell survival. In CD44−/− mice, postpartum uterine involution is accelerated and
maintenance of lactation is impaired. In both uterine and mammary epithelia of these mice, MMP-7
localization is altered and pro-HB-EGF processing as well as ErbB4 activation are decreased. Our observations
provide a mechanism for the assembly and function of a cell surface complex composed of CD44HSPG, MMP
7, HB-EGF, and ErbB4 that may play an important role in the regulation of physiological tissue remodeling.
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The highly polymorphic facultative cell surface proteo-
glycan CD44 is implicated in a variety of cellular func-
tions, including adhesion, migration, activation, inva-
sion, and survival (for review, see Lesley et al. 1993).
Several of these functions have been attributed to the
ability of CD44 to bind hyaluronan (HA; Aruffo et al.
1990; Stamenkovic et al. 1991), for which CD44 appears
to be a major cell surface receptor. However, there is
strong evidence that variant exon usage and cell type-
specific glycosylation endow CD44 with additional prop-
erties. CD44 isoforms containing the variant exon v3
(Screaton et al. 1992) display both biochemical and func-
tional characteristics of heparan sulfate proteoglycans
(HSPGs; Bennett et al. 1995). The v3 exon contains Ser-
Gly repeats that support covalent attachment of high
molecular weight HS side chains (Bartolazzi et al. 1995;
Bennett et al. 1995), which bind selected heparin-binding
growth factors, including basic fibroblast growth factor
(bFGF), heparin-binding epidermal growth factor (HB-
EGF; Bennett et al. 1995), and FGF-8 (Sherman et al.
1998). The physiological relevance of these interactions
has remained largely obscure, and although it has been
suggested that CD44v3 HSPG, henceforth referred to as
CD44HSPG, may present these growth factors to their
specific receptors (Bennett et al. 1995; Sherman et al.
1998), no direct evidence of CD44HSPG participation in
such events in vivo has been provided thus far. Never-
theless, we have observed that CD44-deficient mouse
keratinocytes fail to proliferate in response to HB-EGF
(Kaya et al. 1997), rendering conceivable the notion that
CD44HSPG provides a mechanism for the presentation
of HB-EGF to its receptors.
Interaction of mature HB-EGF with HSPG, via its hep-
arin-binding domain, is required for optimal binding to
its receptors (Higashiyama et al. 1993), which belong to
the ErbB subclass of receptor tyrosine kinases (for re-
view, see Olayioye et al. 2000). Engagement of ErbB re-
ceptors by HB-EGF is implicated in wound healing
(Marikovsky et al. 1993), cell proliferation and migration
(Higashiyama et al. 1993), blastocyst implantation (Raab
et al. 1996), and protection from apoptotic cell death
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(Opanashuk et al. 1999). All six of the known mamma-
lian EGF-related molecules, including EGF, HB-EGF,
transforming growth factor alpha (TGF-), amphiregulin,
betacellulin, and epiregulin are expressed as integral
membrane precursor proteins (Olayioye et al. 2000).
Their activation requires proteolytic removal of the pro-
peptide, and release of the corresponding mature protein
from the cell surface, which can bind or be presented to
ErbB receptors (Olayioye et al. 2000). Although the
mechanisms that underlie the processing of most EGF
family precursors remain unknown, recent evidence sug-
gests that matrix metalloproteinases (MMPs) are in-
volved in the proteolytic cleavage of the HB-EGF precur-
sor (Suzuki et al. 1997; Izumi et al. 1998; Prenzel et al.
1999). This notion is based on the observation that re-
lease of mature HB-EGF from the cell surface is abro-
gated by most hydroxamate-based synthetic MMP in-
hibitors or divalent cation chelating reagents (Suzuki et
al. 1997; Prenzel et al. 1999).
Matrix metalloproteinases and ADAMs are two of the
four subfamilies of the metzincins, which are believed to
play key roles in orchestrating both physiological and
pathological mammalian tissue remodeling (Werb 1997;
Lukashev and Werb 1998; Shapiro 1998; Nagase and
Woessner 1999). There are currently 24 identified
MMPs, most of which are expressed in secreted form,
whose combined activity can degrade all of the extracel-
lular matrix (ECM) proteins (Bode et al. 1996; Vu and
Werb 2000). In addition to ECM proteins, MMPs can
proteolytically activate a variety of ECM- and mem-
brane-bound latent growth factors and cleave cell surface
adhesion receptors (for review, see Murphy and Gavri-
lovic 1999; Bergers and Coussens 2000). Several reports
suggest that cell surface docking of secreted MMPs may
be required for their ability to promote ECM degradation
and latent growth factor processing (Brooks et al. 1996;
Chen 1996; Yu and Stamenkovic 2000). Recently, hepa-
ran sulfate proteoglycans have been proposed to provide
a cell surface docking mechanism for matrilysin/MMP-
7, based on the observation that MMP-7 displays high
affinity for heparan sulfate glycosaminoglycans (GAGs,
Yu and Woessner 2000).
MMP-7 is the smallest known secreted MMP and
lacks the C-terminal hemopexin homology domain,
which is believed to participate in promoting MMP in-
teraction with substrate (Nagase and Woessner 1999). It
is therefore plausible that optimal interaction between
MMP-7 and its substrates requires the intervention of a
third molecule, such as an HSPG, that serves to recruit
both enzyme and substrate to the same site. Matrilysin/
MMP-7 is expressed on the apical surface of intestinal
mucosal, endometrial and glandular epithelial cells, as
well as in carcinomas and mononuclear phagocytic cells
(Woessner 1996), all of which constitutively or inducibly
express CD44HSPG (for review, see Lesley et al. 1993).
Functionally, MMP-7 is implicated in physiological
ECM remodeling during reproductive organ involution
(Woessner 1996; Yu and Woessner 2000), host defense
(Wilson et al. 1999), and tumor survival (Witty et al.
1994; Wilson et al. 1997; Rudolph-Owen et al. 1998).
Here, we address the possibility that CD44HSPG
might direct the assembly of MMP-7, HB-EGF precursor,
and the HB-EGF receptor ErbB4, and thereby provide a
mechanism for the regulation of HB-EGF processing and
function and physiological tissue remodeling.
Results
CD44HSPG recruits MMP-7 to the cell surface
in complex in a broad range of cell types
To determine whether CD44HSPG provides a cell sur-
face docking mechanism for MMP-7 we addressed the
putative interaction between the two molecules in sev-
eral cell types. Following phorbolester stimulation, neu-
roblastoma SH-SY5Y cells were observed to express
CD44HSPG and MMP-7, which colocalized on the cell
surface and along neurite extensions, as assessed by im-
munofluorescence microscopy of cells labeled with anti-
CD44 and anti-MMP-7 antibody (Fig. 1A, top panel).
Similar colocalization was observed when green fluores-
cence protein (GFP)-tagged MMP-7 and v5-his-tagged
CD44v3-10 were transiently expressed in these cells in
the absence of phorbolester stimulation (data not
shown). Introduction of cDNAs encoding human
CD44v3-10 and MMP-7 into CHO cells resulted in the
colocalization of CD44HSPG and MMP-7 at the tips of
cellular processes (Fig. 1A, bottom panel). Such colocal-
ization was not observed when cDNAs encoding CD44
isoforms that do not contain the v3 exon were cotrans-
fected with MMP-7 (data not shown). To determine
whether colocalization of CD44HSPG and MMP-7 is
heparan sulfate-dependent, Ltk− [L-M(TK−)] cells were
transfected with a cDNA encoding CD44v3-10 and
tested for their ability to bind exogenous MMP-7 (con-
taining a E219Q mutation that abrogates catalytic activ-
ity) in the presence and absence of a heparin wash (Fig.
1B). MMP-7 bound poorly to the surface of Ltk− cells but
strongly to Ltk− transfectants expressing CD44v3-10.
Binding was abolished by washing the transfectants with
0.2 mg/mL heparin (Fig. 1B).
We next addressed the colocalization and possible in-
teraction among CD44HSPG, MMP-7, proHB-EGF, and
ErbB4. We selected Namalwa B lymphoma cells for these
experiments because they express MMP-7, HB-EGF, and
ErbB4 but not CD44 (Sy et al. 1991; Bartolazzi et al.
1995). Based on the observed CD44HSPG–MMP-7 colo-
calization in three different cell types, we reasoned that
if CD44HSPG orchestrates the assembly of MMP-7, HB-
EGF, and ErbB4, the event should be general rather than
cell type-specific, and introduction of the appropriate
CD44 isoform into Namalwa cells should reconstitute
the complex on the cell surface. In wild type Namalwa
cells, MMP-7 expression was observed to be intracellular
(data not shown). Stable expression of CD44HSPG in
these cells resulted not only in the intracellular colocal-
ization of CD44 and MMP-7, but also in the localization
of MMP-7 to the cell surface (Fig. 2A, top panel). In con-
trast, CD44 isoforms that do not contain the v3 exon and
lack high molecular weight HS, including CD44H (Fig.
Yu et al.
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2A, bottom panel) and CD44v7-10 (data not shown)
failed to localize MMP-7 to the cell surface.
To verify the formation of a CD44HSPG–MMP-7 com-
plex on the surface of Namalwa transfectants, coimmu-
noprecipitation experiments were performed, in which
cells were incubated with an anti-MMP-7 polyclonal an-
tibody (RM7-C; Yu and Woessner 2000), raised against a
unique C-terminal MMP-7 peptide prior to lysis in a
0.5% Triton-X buffer. The RM7-C antibody does not dis-
play cross reactivity with MMPs 1, 2, 3, 8, 9, and 13, fails
to stain cells that do not express MMP-7 (Yu and Woess-
ner 2000; data not shown), and its reactivity with Na-
malwa CD44HSPG transfectants was abrogated by the
immunogenic peptide (data not shown). Following cell
lysis, the immunoprecipitates were subjected to SDS-
PAGE, transferred onto nitrocellulose membranes and
immunoblotted with anti-CD44 mAb. Among the
RM7-C antibody immunoprecipitates derived from Na-
malwa cells expressing different CD44 isoforms, only
those from CD44HSPG transfectants contained CD44
(Fig. 2B), which appeared as a smear, consistent with the
presence of high molecular weight HS chains (Bartolazzi
et al. 1995). These observations support the notion that
expression of the v3 exon/HS is required for CD44-
MMP-7 complex formation.
To provide further evidence that CD44HSPG associ-
ates with MMP-7, heparin eluates of anti-CD44 mAb
immunoprecipitates derived from CD44v3 transfectants
were subjected to heparin-enhanced CM-transferrin zy-
mogram analysis (Yu and Woessner 2000). Active MMP-
7, as indicated by its molecular weight (Yu and Woessner
2000), could be heparin-eluted from anti-CD44 mAb im-
munoprecipitates of CD44v3 transfectants, and fully or
partially removed from the CD44v3 complexes by hepa-
ritinase or chondroitin lyase ABC treatment, respec-
tively (Fig. 2C). Heparin eluates of immunoprecipitates
of CD44 isoforms that lack the v3 exon, and the associ-
ated HS, did not display MMP-7 activity on CM-trans-
ferrin zymogams (data not shown). These observations
not only support the notion that CD44HSPG provides a
docking mechanism for MMP-7, but also suggest that
most of the MMP-7 associated with CD44HSPG has un-
dergone cleavage of its pro-domain and is proteolytically
active.
Figure 1. Colocalization of CD44HSPG and MMP-7 in cell lines. (A) (Top panel) Phorbolester-treated neuroblastoma SH-SY5Y cells
display colocalization of MMP-7 and CD44HSPG on the cell surface and along neurite extensions (inset). (Bottom panel) CHO cells
cotransfected with cDNAs encoding human CD44v3-10 and MMP-7 display colocalization of the two molecules in cell protrusions.
(B) Recombinant purified MMP-7 binds weakly to Ltk− [L-M(TK−)] cells, but strongly to Ltk− cells transfected with CD44v3-10.
Binding is abrogated by washing the transfectants with 0.2 mg/mL heparin.
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Pro-HB-EGF forms a complex with CD44HSPG and is
a substrate of MMP-7
CD44HSPG binds pro-HB-EGF (Bennett et al. 1995) and
pro-HB-EGF is processed by MMP-type proteolytic activ-
ity (Prenzel et al. 1999). If CD44HSPG provides a cell
surface docking mechanism for MMP-7, it is conceivable
that MMP-7 may be implicated in pro-HB-EGF process-
ing. Mature HB-EGF should then be detected on the sur-
face of CD44HSPG transfectants but not on that of cells
expressing other CD44 isoforms. Consistent with this
notion, neutralizing anti-HB-EGF antibody that recog-
nizes mature forms of HB-EGF but not pro-HB-EGF, re-
acted with the surface of CD44HSPG-expressing Nama-
lwa cells but not with cells transfected with CD44v7-10
and other, HS-negative CD44 isoforms (Fig. 3A, top
panel; data not shown). MMP-7 was observed to colocal-
ize with pro-HB-EGF in CD44HSPG transfectants, as as-
sessed by confocal microscopy (Fig. 3A, bottom panel).
To address the possible association between MMP-7
and HB-EGF in Namalwa transfectants, immunoprecipi-
tation of MMP-7 was performed using a buffer contain-
ing high zinc concentration (50 µM) that inhibits its pro-
teolytic activity (Woessner and Taplin 1988; Yu and
Woessner 2000), and should therefore facilitate coimmu-
noprecipitation of enzyme and substrate. Western blot
analysis of anti-MMP-7 antibody immunoprecipitates
from CD44HSPG Namalwa transfectants, using the
anti-HB-EGF mAb C-18 that recognizes the cytoplasmic
tail of human pro-HB-EGF, revealed the presence of a
single major protein of 28 kD (Fig. 3B). Coimmunopre-
cipitation of MMP-7 and pro-HB-EGF from cells express-
ing CD44 isoforms that do not contain the v3 exon was
not observed (Fig. 3B).
To determine whether MMP-7 is implicated in pro-
HB-EGF processing, pro-HB-EGF coimmunoprecipitated
with CD44HSPG was subjected to MMP-7 proteolysis in
vitro. Protein A-bound anti-panCD44 antibody immuno-
precipitates from CD44v3 Namalwa transfectants were
treated with an EDTA-containing buffer to remove asso-
ciated MMP-7 and any other potential MMP activity.
EDTA can partially denature MMPs by chelating Ca+2
and Zn+2, and thereby disrupt their heparin-binding abil-
ity (Yu and Woessner 2000). The immunoprecipitates
were then washed with PBS containing Mg+2 and Ca+2 to
remove any remaining EDTA and incubated with puri-
fied, Escherichia coli-derived, recombinant active MMP-
7, in the presence and absence of the synthetic MMP
inhibitor SC44463 whose IC:50 for MMP-7 is 10 nM
(Butler et al. 1991; Abramson andWoessner 1994; Yu and
Woessner 2000). In the presence of the inhibitor, as in
the absence of MMP-7, immunoblotting with a combi-
nation of neutralizing anti-HB-EGF and C-18 anti-pro-
HB-EGF antibodies, revealed three major species of HB-
EGF with a molecular weight ranging between 22 and 28
kD (Fig. 3C). The 28-kD species corresponds to that of
pro-HB-EGF coimmunoprecipitated with MMP-7 (Fig.
3B). In the absence of inhibitor, immunoblotting with
Figure 2. Reconstitution of the CD44HSPG/
MMP 7/HB-EGF/ErB4 complex in Namalwa
cells. (A) Confocal microscopy of Namalwa CD44
transfectants incubated with anti-CD44 (red fluo-
rescence) and anti-MMP-7 (green fluorescence)
mAb. Namalwa transfectants expressing
CD44v3-10 (top) and CD44H (bottom) are shown.
(B) Coimmunoprecipitation of CD44v3 and
MMP-7. Indicated Namalwa transfectants were
incubated with anti-MMP-7 C-M7 antibody,
washed extensively, and lysed. Lysates were in-
cubated with protein A sepharose beads and the
immunoprecipitates were subjected to SDS-
PAGE, transferred onto Hybond-C nitrocellulose
membranes and immunoblotted with anti-CD44
mAb. (C) Transferrin zymogram of heparin elu-
ates from anti-CD44 antibody immunoprecipi-
tates of Namalwa CD44v3.8-10 and CD44v3-10
transfectant lysates (left). Transferrin zymogram
of chondroitin lyase (Ch)− and heparanase (Hep)-
treated anti-CD44 mAb immunoprecipitates
from CD44v3-10 and CD44v7-10 Namalwa trans-
fectants (right). C1 and C2 are control lanes con-
taining protein A beads only (C1) and heparinase,
chondroitinase, and digestion buffer in the ab-
sence of substrate (C2). MMP-3 (M3) and pro- and
active-recombinant MMP-7 (M7) are used as
marker controls. Migration of pro- and active
MMP-7 are indicated on the left along with the
molecular weight markers.
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the same two antibodies revealed at least four HB-EGF
species of 10, 14, 18, and 19 kD (Fig. 3C). The size of
these species is consistent with those believed to repre-
sent the active HB-EGF forms observed in the lysates and
conditioned culture media of cells stimulated with phor-
bolester and kinaic acid (Opanashuk at al. 1999; Gecht-
man et al. 2000).
ErbB4 associates with several CD44 isoforms but is
tyrosine phosphorylated predominantly when
associated with CD44HSPG
The observations that CD44HSPG isoforms form a com-
plex with MMP-7 and HB-EGF, and that pro-HB-EGF
may be an MMP-7 substrate are consistent with the pos-
sibility that CD44HSPG may present the processed HB-
EGF to its receptor(s). HB-EGF binds to the ErbB receptor
tyrosine kinase family, and more specifically, to ErbB1 or
ErbB4 (for review, see Olayioye et al. 2000). ErbB4 was
observed to colocalize with a variety of CD44 isoforms
in Namalwa transfectants (Fig. 4A). However, Western
blot analysis of anti-CD44 antibody immunoprecipitates
using anti-phosphotyrosine mAb, revealed tyrosine
phosphorylation of ErbB4 (185 kD) predominantly in im-
munoprecipitates derived from CD44HSPG transfec-
tants (Fig. 4B, top panel). Only minor ErbB4 tyrosine
phosphorylation was observed in transfectants express-
ing non-v3 exon-containing CD44 isoforms, including
CD44H, v6-10 and v7-10, even though ErbB4 was found
to coimmunoprecipitate comparably with all of the
CD44 variants tested (Fig. 4B, bottom panel). Pretreat-
ment of cells with 50 ng/mL of neutralizing anti-HB-EGF
antibody strongly diminished ErbB4 tyrosine phosphory-
lation, as did preincubation of the cells with MMP in-
hibitors SC44463, BB94 and TIMP-3 and the pro-MMP-
7E219Q mutant that displays a 590-fold reduction in ac-
tivity (Cha and Auld 1997; Fig. 4C). These observations
support the notion that CD44HSPG may present active
HB-EGF to ErbB4. Consistent with this view, addition of
recombinant mature HB-EGF rescued ErbB4 tyrosine
phosphorylation in CD44HSPG transfectants incubated
with pro-MMP-7E219Q, but had no effect on ErbB4 ty-
rosine phosphorylation in CD44H and CD44v7-10 trans-
fectants (data not shown).
MMP-7 has been proposed to promote tumor cell sur-
vival (Witty et al. 1994), and HB-EGF has been impli-
cated in the protection of cells from apoptosis
(Opanashuk et al. 1999). Consistent with these observa-
Figure 3. HB-EGF association with and processing
by MMP 7. (A) (Top panel) Localization of HB-EGF
on the surface of CD44v3 isoform expressing Na-
malwa cells, as assessed by neutralizing anti-HB-
EGF antibody reactivity. (Bottom panel) Colocaliza-
tion of proHB-EGF (C-18 antibody) and MMP-7
(RM7-C antibody) in Namalwa cells transfected
with CD44v3-10, as assessed by confocal micros-
copy (magnification, 63×). (B) Coimmunoprecipita-
tion of HB-EGF and MMP-7. MMP-7 was immuno-
precipitated from Namalwa cells expressing the in-
dicated CD44 isoforms with the indicated anti-
MMP-7 antibody. The immunoprecipitates were
subjected to SDS-PAGE, transferred onto nylon fil-
ters, and immunoblotted with the indicated anti-
HB-EGF mAb. Lanes indicated pep C-18 and Mock
C, respectively denote immunoprecipitates in the
presence of immunogenic peptide and immunopre-
cipitates derived from vector only transfectants. (C)
Proteolytic cleavage of pro-HB-EGF by MMP-7. Na-
malwa transfectant-derived anti-CD44 mAb immu-
noprecipitates were washed with a buffer containing
EDTA to remove the coimmunoprecipitatedMMP-7
and any other possibly associated MMP activity.
The immunoprecipitates were then incubated with
recombinant active MMP-7 in the presence or ab-
sence of the synthetic inhibitor SC44463 and sub-
jected to SDS-PAGE, transfer to nitrocellulose mem-
branes, and immunoblotting with a combination of
neutralizing and cytoplasmic domain anti-HB-EGF
mAb. Molecular weight markers are indicated.
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tions, recombinant active MMP-7 and mature HB-EGF
were each observed to rescue Namalwa CD44HSPG
transfectants from serum starvation-induced cell death,
whereas synthetic MMP inhibitors as well as anti-HB-
EGF neutralizing antibody promoted apoptosis (data not
shown). Significantly, neither recombinant MMP-7 nor
HB-EGF could rescue wild type Namalwa cells and
transfectants expressing non-HSPG isoforms of CD44
from serum deprivation-induced apoptosis (data not
shown).
To address the role of MMP-7 in the Namalwa cell
survival more selectively, we tested the effect of recom-
binant rat proMMP-7E219Q, which should compete
with endogenous MMP-7 for binding to the surface of
CD44HSPG-transfected Namalwa cells. Namalwa trans-
fectants incubated with the recombinant mutant pro-
MMP-7E219Q were stained with an antibody that spe-
cifically recognizes the prodomain of rat but not the en-
dogenous human MMP-7 (RM7-N, Fig. 4D). Pro-MMP-
7E219Q was observed to form aggregates on the surface
of CD44HSPG transfectants (Fig. 4D, middle panel), but
failed to bind transfectants expressing CD44 isoforms
that lack the v3 exon (data not shown). Most of the cells
that bound the mutant enzyme tested positive for
TUNEL staining (Fig. 4D, middle panel), but could be
rescued from apoptosis by the addition of recombinant
active HB-EGF (Fig. 4D, right panel). Comparable results
were obtained using phorbolester-stimulated neuroblas-
toma SH-SY5Y cells grown in soft agar (data not shown).
Postpartum uterus involution in CD44−/− mice is
accelerated and accompanied by MMP-7
redistribution and decreased HB-EGF processing
To determine whether recruitment of MMP-7, pro-HB-
EGF, and ErbB4 is a physiological function of
Figure 4. ErbB4 complexes with CD44 but is phosphorylated preferentially when associated with CD44v3. (A) Confocal microscopy
shows colocalization of ErbB4 (red fluorescence) and CD44 (green fluorescence) in Namalwa CD44 transfectants. (B) (Top panel)
Western blot analysis of anti-CD44 mAb immunoprecipitates from Namalwa transfectant lysates using anti-phosphotyrosine mAb
pY20. (Bottom panel) Western blot analysis of anti-CD44 mAb immunoprecipitates in B immunoblotted with anti-c-ErbB4 mAb
HFR-1. (C) HB-EGF neutralizing Ab (100 ng/mL), proMMP-7E219Q mutant (300 ng/mL), TIMP-3 (100 ng/mL), and MMP inhibitors
SC44463 and BB94 (50 ng/mL) can reduce the level of tyrosine phosphorylated ErbB-4 in CD44V3-10 transfected Namalwa cells. (Top
panel) Anti-tyrosine Ab pY20 blot. (Bottom panel) Anti-C-erbB-4 Ab-4 (HFR-1) blot. (D) Pro-MMP-7E219Q binds to the surface of
Namalwa CD44HSPG and promotes apoptosis in serum-free medium. Namalwa transfectants expressing CD44v3-10 were incubated
in serum free medium in the presence or absence of 100 ng/mL of recombinant proMMP-7E219Q alone or proMMP-7E219Q and
recombinant active HB-EGF (50 ng/mL) as indicated. The cells were then tested for cell surface-bound MMP 7E219Q, using rat
N-terminal propeptide MMP-7-specific antibody RM7-N (red fluorescence), and apoptosis, as assessed by TUNEL staining (green
fluorescence). The RM7-N antibody did not react with CD44v3-10 Namalwa transfectants in the absence of exogenous rat proMMP
7E219Q (left). RM7-N stained CD44v3-10 Namalwa transfectants incubated with pro-MMP 7E219Q, but not CD44 transfectants
lacking HSPG (data not shown). The majority of MMP-7E219Q bound cells tested TUNEL positive. Recombinant active HB-EGF (50
ng/mL) bound to the surface of transfectants preincubated with proMMP 7E219Q, as assessed by staining with neutralizing anti-HB-
EGF antibody (right) and could rescue the majority of the cells from MMP 7E219Q binding-induced apoptosis.
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CD44HSPG, we explored the assembly of the complex in
organs of wild-type and CD44-null DBA/1 mice that ex-
press both CD44 and MMP-7. CD44 is broadly expressed
in human and mouse tissues, but CD44HSPG appears to
be preferentially expressed in epithelia, including among
others, postpartum uterine (W-H. Yu and I. Stamenko-
vic, unpubl.) and mammary gland epithelial (Roca et al.
1998) cells. MMP-7 expression has been detected in the
epithelium of numerous organs, which in the mouse in-
clude the colon, kidney, lung, skin, stomach, postpartum
uterus, and lactating and involuting mammary gland
(Wilson et al. 1995). Because we observed DBA/1 CD44-
null mice to display premature postpartum uterine and
lactating mammary gland involution, we focused our at-
tention on MMP-7/HB-EGF/ErbB4 localization and ac-
tivity in these organs in wild-type and CD44−/− animals.
Heparan sulfate expression in the uterine epithelium
varies during the estrous cycle, reaching a peak between
24 and 36 h postpartum (Yu and Woessner 2000), and
closely mimics that of MMP-7 (Sellers and Woessner
1980; Wilson and Matrisian 1996; Woessner 1996). In the
rat, MMP-7 proteolytic activity is present at term and its
concentration rises to a peak between 24 and 36 h post-
partum, which coincides with maximal glycoprotein and
proteoglycan loss (Sellers and Woessner 1980). It then
falls to near undetectable levels by five days postpartum.
MMP-7 transcripts in the mouse uterus show a similar
pattern, with the appearance of a distinct signal in the
epithelium during pregnancy that reaches maximal
strength between 6 and 36 h postpartum (Wilson and
Matrisian 1996). Interestingly, postpartum involution of
the uterus appeared to be accelerated in CD44-null
DBA/l mice (Fig. 5A, a). At term, the size of the uterus in
wild-type and CD44−/− animals was comparable (data
not shown). However, 24–36 h postpartum, the size of
CD44−/− mouse uterus was reduced to about half that of
wild-type animals (Fig. 5A, a). Low power histological
comparison revealed reduced wall thickness of postpar-
tum uteri from CD44−/− mice, with a disorganized myo-
metrium (Fig. 5A, b,c). At higher power, morphological
changes were observed in both the epithelial (Fig. 5A,
d,e) and smooth muscle layers (Fig. 5A, f,g). Lumenal
epithelial cells in CD44−/− postpartum uteri displayed a
more elongated, columnar morphology than their wild-
type counterparts, with elongated nuclei (Fig. 5A, d,e).
The compact disposition of wild-type myometrial
smooth muscle bundles (Fig. 5A, f) was replaced by
loosely coordinated, disorganized groups of smooth
muscle cells with dense, slightly hyperchromatic nuclei
(Fig. 5A, g).
Confocal microscopy revealed colocalization of
CD44HSPG and MMP-7 on the apical surface of wild-
type postpartum endometrial epithelial cells (Fig. 5B, top
panel). In contrast, MMP-7 displayed a more diffuse,
basal distribution in the epithelium of CD44−/− postpar-
tum uteri (Fig. 5B, second panel), consistent with the
possibility that CD44HSPG provides an apical cell sur-
face-docking molecule for MMP-7. The redistribution of
MMP-7 in the absence of CD44 is further illustrated by
comparing anti-MMP-7 and anti-perlecan (a basement
membrane proteoglycan) antibody staining of postpar-
tum uterine epithelium in wild-type and CD44−/− mice.
Whereas MMP-7 and perlecan localize to the apical cell
surface and basement membrane, respectively, in wild-
type mice (Fig. 5B, third panel), they colocalize in the
basal cell compartment and in the basement membrane
in CD44−/− mice (Fig. 5B,bottom panel).
The anti-HB-EGF neutralizing antibody that selec-
tively recognizes the processed, mature form of HB-EGF
reacted with the apical surface of uterine epithelial cells
in wild-type mice, similar to the anti-MMP-7 antibody
(Fig. 5C, top panel). Unlike MMP-7, pro-HB-EGF, recog-
nized by the M-18 antibody raised against its intracellu-
lar domain, remained on the apical surface in CD44−/−
epithelial cells (Fig. 5C, middle panel). However, the
neutralizing anti-HB-EGF antibody only faintly stained
the epithelial surface in CD44−/− animals (Fig. 5C, bot-
tom panel), consistent with the possibility that pro-HB-
EGF processing is attenuated when MMP-7 is not on the
apical cell surface. Postpartum uterine smoothmuscle in
CD44−/− animals displayed similar phenotypic changes
to those seen in the epithelium, with redistribution of
MMP-7 to the periphery of the fibers (Fig. 5D, top and
middle panels) and marked reduction in pro-HB-EGF pro-
cessing (Fig. 5D, bottom panel).
The evidence that the EGF receptor family member
ErbB 4 is an HB-EGF receptor (Olayioye et al. 2000;
Sweeney et al. 2000) predicts that ErbB4 should display a
similar tissue and cellular distribution to that of
CD44HSPG and MMP-7, and that its activation, as de-
fined by its tyrosine phosphorylation (Sweeney et al.
2000), should be detected at these sites. As expected,
ErbB4 expression was observed predominantly on the
apical surface of uterine epithelium and throughout the
smooth muscle fibers (Fig. 5E; data not shown). More-
over, an anti-phosphotyrosine antibody reacted strongly
with the apical epithelial surface of uteri from wild-type
mice (Fig. 5E, top panel). In CD44−/− animals, ErbB4 ex-
pression was unaltered, but tyrosine phosphorylation of
molecules associated with the apical epithelial cell
membrane was barely detectable (Fig. 5E, bottom panel).
Because of the observation that HB-EGF can protect cells
from apoptosis (Opanashuk et al. 1999), postpartum
wild-type and CD44−/− uterine tissues were compared for
apoptotic cell death by TUNEL assay. Whereas there was
little detectable apoptosis in the epithelium and smooth
muscle of wild-type 24–48 h postpartum uteri (Fig. 5F,
top and third panels), extensive apoptosis in both tissues
was observed in CD44−/− counterparts (Fig. 5F, second
and bottom panels).
Lactating mammary gland undergoes premature
involution in CD44−/− DBA/1 mice
On average, six to eight out of 10 CD44−/− DBA/l mice
(from a total of 20 litters) were observed to die within
2 d after birth because of the impaired ability of the fe-
males to nurse. When nursed by surrogate wild-type
mothers, CD44−/− pups develop normally, whereas 60–
80% of wild-type type pups nursed by CD44−/− females
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(5–6 wild-type pups per surrogate CD44-null mother in
5 experiments) die. CD44-null females do not appear to
neglect their pups, and in fact bear numerous bite marks
on their nipples that reflect the pups’ attempts to feed
(data not shown). These observations are consistent with
the possibility that CD44-null mammary glands bear a
developmental and/or functional defect. Mammary
gland development in CD44-null mice at puberty was
comparable to that in wild-type counterparts as judged
by conventional histology (data not shown). However,
unlike postpartum mammary glands in wild-type mice,
which involute after weaning, most CD44−/− mouse
mammary glands were found to undergo involution
within 1–4 d postpartum (Fig. 6A, a; data not shown). At
2 d postpartum, mammary fat pads of wild-type females
were nearly completely invested with engorged lobuloal-
veoli that displaced stromal adipose tissue (Fig. 6A, b,d).
In contrast, mammary glands of CD44−/− mice displayed
(Figure 5 continued on facing page)
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only focal lobuloalveolar expansion (Fig. 6A, c), with
many of the acini appearing condensed, and containing
lumenal secretory lipids (Fig. 6A, e). Whereas wild-type
mammary gland epithelium was largely negative for
TUNEL staining (Fig. 6A, f), numerous TUNEL-positive
cells were observed in the epithelium of CD44−/− mam-
mary glands (Fig. 6A, g), consistent with extensive apop-
totic cell death.
Similar to the uterine epithelium, the lobuloalveolar
epithelium of lactating mammary glands displayed
CD44HSPG and MMP-7 colocalization on the lumenal
surface (Fig. 6B, top panel; data not shown). Similar co-
localization was observed in myoepithelial cells (data
not shown). In CD44−/− mice, MMP-7 was observed to
undergo basal redistribution (Fig. 6B, second panel), as
verified by comparison with perlecan localization (Fig.
6B, lower two panels). Whereas acini of wild-type mice
displayed apico-lateral epithelial cell MMP-7 and base-
ment membrane perlecan distribution (Fig. 6B, third
panel), the two molecules colocalized to the basal cellu-
lar and basement membrane compartments in the acini
of CD44−/− animals (Fig. 6B, bottom panel). Mature HB-
EGF colocalized with MMP-7 in the acinar mammary
gland epithelium of wild-type mice (Fig. 6C, top panel),
but was only weakly visible in the acini of CD44−/−
counterparts (Fig. 6C, middle panel), whereas pro-HB-
EGF expression remained localized throughout the epi-
thelial cells (Fig. 6C, bottom panel). Expression of ErbB4
appeared to be unaltered in CD44−/− mice, but tyrosine
phosphorylation in the apical epithelial cell compart-
ment (Fig. 6D, top panel) was greatly diminished (Fig.
6D, bottom panel). These alterations in MMP-7 and HB-
EGF distribution, and tyrosine phosphorylation associ-
ated with the apical epithelial cell membrane are similar
Figure 5. CD44 regulates postpartum uterus remodeling. (A).
Gross anatomy (a) and histology (b–g) of 36 h postpartum uteri
from wild-type (+/+) and CD44 deficient (−/−) DBA/l mice.
Note the comparable diameter of the cervix (a). Low power (8×)
magnification of uterine cross-sections shows a preserved en-
dometrial and myometrial structure in wild-type postpartum
uterus (b) that contrasts with disorganized architecture of the
CD44−/− counterpart (c), characterized by the loss of myome-
trial mass. Higher magnification (40×) shows predominantly
round nuclei in the epithelial cells of wild-type uterus (d) com-
pared to elongated, hyperchromatic nuclei in the more colum-
nar epithelial cells of CD44−/− uterus (e). Smooth muscle lay-
ers are preserved in wild-type uterus (f), but appear disorganized and condensed, with hyperchromatic nuclei in CD44−/− uterus (g). (B)
CD44HSPG-dependent localization of MMP-7 to the apical surface of uterine epithelium. (Top panels) 36 h postpartum uteri from
wild-type and CD44−/− mice were stained with anti-CD44v3 mAb (red fluorescence) and anti-MMP-7 mAb (green fluorescence).
(Bottom panels) Comparison of the localization of anti-MMP-7 antibody staining to that of anti-basement membrane proteoglycan
perlecan antibody staining in 36 h postpartum epithelium of wild-type and CD44−/− mice. White and red arrows indicate the apical and
basal epithelial surface, respectively. (C) MMP-7 and HB-EGF localization in wild-type and CD44−/− uterine epithelium. Thirty-six h
postpartum uteri from wild-type and CD44−/− mice were stained with anti-MMP-7 antibody (red fluorescence) and anti-HB-EGF
neutralizing antibody that recognizes the mature form only (HB-EGF), or the C-18 antibody against a peptide in the cytoplasmic tail
of pro-HB-EGF (proHB-EGF, green fluorescence). White and red arrows denote the apical and basal epithelial surface, respectively. (D)
MMP-7 and HB-EGF localization in wild-type and CD44−/− postpartum uterine smooth muscle. Staining was performed as in C and
shows colocalization of MMP-7 and mature HB-EGF in wild-type smooth muscle cells (top). In CD44−/− postpartum uteri, MMP-7 is
redistributed to the cell periphery, MMP-7 and pro-HB-EGF show only occasional colocalization (middle), and mature HB-EGF is
barely detectable (bottom). (E) Colocalization of ErbB4 and phosphotyrosine in postpartum uterine epithelium. Anti-ErbB4 antibody
(red fluorescence) and anti-phosphotyrosine pY20 mAb (green fluorescence) predominantly stain the apical epithelial surface in
wild-type postpartum uterus (top). In CD44−/− postpartum uterus, ErbB4 distribution is unchanged, whereas apical epithelial tyrosine
phosphorylation is abrogated, and only intracellular phosphorylation remains detectable. White and red arrows indicate the apical and
basal epithelial surface, respectively (F) TUNEL (green fluorescence) and anti-CD44 mAb staining (red fluorescence) in wild-type and
CD44−/− 48 h postpartum uteri. Wild-type (top) and CD44−/− (second panel) epithelial, and wild-type (third panel), and CD44−/− smooth
muscle (bottom) staining is shown, indicating massive apoptotic cell death in both cell types in the absence of CD44.
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Figure 6. Implication of CD44 in lactating mammary gland mainte-
nance. (A) Gross anatomy and histology of mammary glands 48 h post-
partum: (a) mammary glands in CD44−/− animals appear to have invo-
luted in comparison to wild-type counterparts; (b–e) low (8×) and high
(64×) magnification of mammary gland tissue sections. Whereas wild-
type mammary gland shows full lobuloalveolar development (b,d),
CD44−/− mammary gland shows segmental development, with few nor-
mal-appearing acini and a large number of condensed acini with hyper-
chromatic nuclei (c,e, arrows). Whereas wild-type mammary tissue is
TUNEL negative (f), CD44−/− mammary epithelium displays abundant
TUNEL staining (g). (B) MMP-7 and CD44HSPG localization in mam-
mary glands of 48 h postpartum wild-type (top) and CD44−/− (second
panel) mice. Staining was performed as in Figure 1. MMP-7 localization
is compared to that of perlecan in wild-type (third panel) and CD44−/−
(bottom) mice. White and red arrowheads indicate the apical and basal
epithelial surface, respectively, and L denotes the acinar lumen. (C) Ma-
ture HB-EGF (a-HB-EGF) and precursor HB-EGF (pro-HB-EGF) localiza-
tion in 2 d postpartum mammary glands in wild-type and CD44−/− mice.
(Top) Mature HB-EGF and MMP-7 localization in mammary glands of
wild-type mice. (Middle and bottom) Mature and pro-HB-EGF localization in comparison to MMP-7 in mammary glands of CD44−/−
mice. White arrows indicate the lumenal epithelial surface. (D) Localization of phosphotyrosine (pY) and ErbB4 in wild-type and CD44−/−
mammary epithelium. Tyrosine phosphorylation is greatly reduced in CD44−/− epithelium whereas ErbB4 expression is unaltered.
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to those observed in the epithelium and smooth muscle
of postpartum uterus.
MMP-7 has been proposed to be weakly expressed in
lactating and involuting mouse mammary gland, detect-
able only by RT–PCR (Wilson et al. 1995). Our results,
however, suggest relatively abundant expression. This
discrepancy may be attributable, in part, to the different
detection methods used, one study analyzing transcript
and the other protein expression using a sensitive anti-
body. It is conceivable that differences in protein and
corresponding transcript stability might account, at least
in part, for higher protein expression than might be pre-
dicted by mRNA levels. Differences in mouse strains
(lCR mice in the study by Wilson et al., and DBA/1 mice
in the present work) may also underlie expression level
variation.
Pro-HB-EGF processing and ErbB4 tyrosine
phosphorylation are reduced in CD44−/− postpartum
uteri and lactating mammary glands
To provide further evidence that pro-HB-EGF processing
is reduced in postpartum uteri and lactating mammary
glands of CD44−/− mice, and to verify that the reduction
of tyrosine phosphorylation observed on tissue sections
is attributable, at least in part to that of ErbB4, we as-
sessed pro-HB-EGF expression and ErbB4 tyrosine phos-
phorylation in the relevant tissues. Western blot analysis
of HB-EGF expression was performed on lysates of wild-
type and CD44−/− 24–36 h postpartum uteri and lactating
mammary glands, using a combination of the M-18 an-
tibody that recognizes pro-HB-EGF and neutralizing
anti-HB-EGF antibody that recognizes processed HB-
EGF only. Immunoprecipitation studies have shown that
HB-EGF precursor can be expressed as several species
ranging between 22 and 30 kD that vary among cell
types, possibly due to posttranslational modifications
(Suzuki et al. 1997; Opanashuk et al. 1999; Prenzel et al.
1999; Gechtman et al. 2000). Processed, mature forms
display a molecular weight range of 14–19 kD
(Opanashuk et al. 1999; Prenzel et al. 1999; Gechtman et
al. 2000). Using the combination of M-18 and neutraliz-
ing anti-HB-EGF antibodies, which allows recognition of
both precursor and processed HB-EGF, we observed a
comparable band pattern on uterine and mammary tis-
sue Western blots (Fig. 7A). Moreover, whereas wild-type
tissues contained several HB-EGF species, ranging from
12–28 kD, consistent with both processed and precursor
forms (Opanashuk et al. 1999; Gechtman et al. 2000),
CD44−/− tissues predominantly displayed the 27–28 kD
species characteristic of pro-HB-EGF (Fig. 7A). Western
blot analysis, using anti-phosphotyrosine antibody pY20,
of ErbB4 immunoprecipitates from wild-type and
CD44−/− postpartum uterine and lactating mammary
gland homogenates, revealed a strong reduction in tyro-
sine phosphorylation of ErbB4 derived from CD44−/− tis-
sues (Fig. 7B).
Discussion
In the present work, we have uncovered two possibly
related functions of CD44. The first is the assembly by
CD44HSPG of a cell surface complex composed of
MMP-7, pro-HB-EGF, and ErbB4. The second is partici-
pation in the regulation of postpartum uterine and lac-
tating mammary gland involution. Assembly of the
MMP-7/HB-EGF/ErbB4 complex, and appropriate local-
ization of MMP-7 proteolytic activity to the epithelial
and smooth muscle cell surface may provide at least part
of the mechanism whereby CD44 regulates female re-
productive organ remodeling.
CD44HSPG-dependent cell surface localization
of MMP-7 and complex assembly
Evidence from both in vivo and in vitro studies, suggests
that CD44HSPG plays a central role in the assembly of
the MMP-7/HB-EGF/ErbB4 complex in the appropriate
cellular location. In the absence of CD44HSPG, MMP-7
was observed to undergo redistribution in postpartum
uterine endometrial cells as well as in lactating mam-
mary epithelial cells from the apical to the basal com-
partment. One possible explanation for this relocaliza-
Figure 7. HB-EGF processing and ErbB4 tyrosine phosphoryla-
tion in 48 h postpartum uteri and lactating mammary glands of
wild-type and CD44−/− mice. (A) 48 h postpartum uterine (U)
and lactating mammary gland (M) lysates (∼80 µg of lysate per
lane) from the indicated animals were tested for HB-EGF ex-
pression by Western blot analysis using a combination of anti-
pro-HB-EGF C-18 and neutralizing anti-HB-EGF antibodies.
Anti-tubulin antibody (bottom) was used as a loading control.
(B) Western blot analysis (top) of anti-ErbB4 antibody immuno-
precipitates (bottom) from 48 h postpartum uteri (U) and lactat-
ing mammary glands (M) using anti-pY20 antibody.
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tion is that in the absence of CD44HSPHG, MMP-7
binds to alternative HSPG docking sites that are pre-
dominantly expressed on the basal surface of epithelial
cells and in the basement membrane. Redistribution of
MMP-7 was accompanied by decreased pro-HB-EGF pro-
cessing, as illustrated by the reduction of mature but not
pro-HB-EGF expression in the epithelium, and inhibition
of ErbB4 tyrosine phosphorylation. Similar observations
were made in uterine smooth muscle, suggesting that in
the absence of CD44, the MMP-7/HB-EGF/ErbB4 com-
plex cannot be assembled in the mouse postpartum
uterus and lactating mammary gland.
The ability of CD44HSPG, but not other CD44 iso-
forms, to reconstitute a functional MMP-7/HB-EGF/
ErbB4 complex in CD44-negative lymphoma cells, not
only supports the notion that CD44HSPG coordinates
MMP-7 and HB-EGF association in vivo, but, consistent
with previous studies (Bennett et al. 1995; Yu and
Woessner 2000), underscores the requirement for hepa-
ran sulfate for the recruitment of both molecules. It also
suggests that the ability of CD44HSPG to assemble the
complex is a general phenomenon that is likely to be
observed in most cells that express the constituent mol-
ecules. A hypothetical representation of the assembly
and function of the CD44HSPG/MMP-7/HB-EGF/ErbB4
complex is shown in Figure 8. In this model, MMP-7 and
pro-HB-EGF are recruited to the cell surface by the HS
chains of CD44HSPG. MMP-7 proteolytically processes
pro-HB-EGF, and mature HB-EGF is presented by the
CD44-associated HS to ErbB4, which is connected to
CD44 by a hypothetical intracellular adaptor protein.
Engagement by HB-EGF induces tyrosine phosphoryla-
tion of ErbB4 and the transduction of signals that can
trigger proliferation, differentiation, and survival.
MMP-7-mediated HB-EGF processing and cell survival
Pro-HB-EGF is expressed as an integral membrane pro-
tein of 22–28 kD, depending, in part, on posttranslational
modification (Higashiyama et al. 1992, 1993; Gechtman
et al. 2000). Stimulation of pro-HB-EGF-producing cells
with phorbolester and other mitogens results in the re-
lease of mature soluble 14–19 kD HB-EGF polypeptides
that function in autocrine or paracrine fashion
(Opanashuk et al. 1999; Prenzel et al. 1999; Gechtman et
al. 2000). Postpartum uterine and lactating mammary
gland lysates from wild-type mice in the present study,
revealed the presence of several HB-EGF species, ranging
from 12–28 kD, consistent with those released from
phorbolester-stimulated tumor cells (Gechtman et al.
2000) and kinaic acid-stimulated neurons (Opanashuk et
al. 1999). In contrast, the corresponding lysates from
CD44−/− animals predominantly displayed 27–28 kD
species that are consistent with pro-HB-EGF. These ob-
servations provide biochemical evidence that in the ab-
sence of the CD44HSPG-assembled complex, pro-HB-
EGF processing is reduced in the uterus and mammary
gland. Incubation of CD44HSPG-associated pro-HB-EGF
with recombinant active MMP-7 resulted in the genera-
tion of 8–19 kD peptides consistent with the reported
mature species (Opanashuk et al. 1999; Prenzel et al.
1999; Gechtman et al. 2000). CD44HSPG-associated pro-
HB-EGF processing was not observed in the presence of
EDTA, which removes endogenous MMPs, and occurred
only when exogenous recombinant active MMP-7 was
added. These observations indicate that pro-HB-EGF is a
substrate of MMP-7.
Thus far, at least two candidate proteolytic enzymes
have been proposed to process pro-HB-EGF. One is
ADAM 9 (Izumi et al. 1998), although this claim is dis-
puted (Prenzel et al. 1999). The other is MMP-3 (Suzuki
et al. 1997). The relative contribution of MMP-3 and
MMP-7 to pro-HB-EGF processing remains to be deter-
mined. The coexpression of MMP-7 and HB-EGF in the
uterus and mammary gland, and their shared affinity for
HSPG, suggest that MMP-7may provide a major process-
ing mechanism for pro-HB-EGF in these tissues. Consis-
Figure 8. Hypothetical assembly and
function of the CD44HSPG/MMP 7/HB-
EGF/ErbB4 complex. CD44HSPG iso-
forms bind proHB-EGF and active MMP-7.
MMP-7 proteolytically cleaves proHB-
EGF, generating mature HB-EGF, which is
presented by CD44HSPG to ErbB4. En-
gagement of ErbB4 by HB-EGF results in
tyrosine phosphorylation of its intracellu-
lar domain and the transduction of signals
that promote survival. ErbB4 may be in-
duced to form homodimers or multimers.
Indirect intracellular domain-mediated in-
teraction between CD44 and ErbB4 is pro-
posed, based on the presence of PDZ bind-
ing motifs in the intracellular domain of
both CD44 (Stamenkovic et al. 1991) and
ErbB4 (Garcia et al. 1999), which may bind
a common scaffold protein. The mecha-
nism of interaction between CD44 and
ErbB family members is presently un-
known and the representation is purely
speculative.
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tent with this view, MMP-3 expression displayed a pre-
dominantly stromal distribution in the uterus and mam-
mary gland in wild-type mice, and was absent in
Namalwa cells (data not shown). However, this neither
invalidates the role of MMP-3 as a pro-HB-EGF proces-
sor, nor does it exclude the possibility that MMP-3 may
play a more dominant role in other situations, such as
stromal remodeling in inflammation and repair.
HB-EGF has been proposed to protect cells from apop-
tosis (Opanashuk et al. 1999). However, in addition to
processing pro-HB-EGF, MMP-7 has been shown to
cleave FasL (Powell et al. 1999), whose effectiveness in
triggering Fas-mediated tumor cell death is reduced in
soluble form (Schneider et al. 1998). MMP-7 may there-
fore protect cells from apoptosis by more than one
mechanism. The Namalwa cells used in the present
study do not express Fas, and the observations that re-
combinant active MMP-7 and mature HB-EGF can each
rescue Namalwa CD44HSPG transfectants from serum
starvation-induced apoptosis, suggest that processing of
pro-HB-EGF in the context of CD44HSPG provides a
plausible mechanism whereby MMP-7 promotes cell
survival.
The possible role of the CD44HSPG/MMP-7/HB-EGF/
ErbB4 complex in postpartum uterine and lactating
mammary gland involution
Postpartum uterine involution in CD44−/− animals was
observed to be accelerated in comparison to that in nor-
mal counterparts, and was accompanied by extensive ep-
ithelial and smooth muscle cell apoptosis. Similarly,
most lactating mammary glands in these animals were
characterized by varying degrees of lobuloalveolar con-
densation with only focal acinar expansion, suggesting
that the lactating phenotype in DBA/1 mice cannot be
fully sustained in the absence of CD44. Because CD44
fulfills multiple functions, including that of a cell sur-
face hyaluronan receptor, any attribution of the regula-
tion of female reproductive organ remodeling to a single
function of CD44 must be made with caution. Never-
theless, it is tempting to speculate that the premature
postpartum uterine and lactating mammary gland invo-
lution observed in CD44-null mice is related to the dis-
ruption of the CD44HSPG-dependent complex. To pro-
vide a plausible suggestion for such a relationship, the
observation that MMP-7 null mice do not display aber-
rant remodeling of either organ (Rudolph-Owen et al.
1997) must be taken into account. The premature repro-
ductive organ involution displayed by CD44−/− mice
may therefore be related not to the loss of MMP-7 activ-
ity, but rather to its mislocalization. Redistribution of
MMP-7 to the basal compartment of CD44−/− epithelial
cells, whether in the uterus or mammary gland, may
have at least two consequences. The first is impaired
pro-HB-EGF processing on the epithelial cell surface re-
sulting in the reduction of ErbB4 activation and genera-
tion of the corresponding survival signals. The second is
inappropriate concentration of MMP-7 proteolytic activ-
ity on the basal surface of epithelial cells, and in the
basement membrane, leading to basement membrane
degradation and potential activation of other locally se-
questered MMPs. ECM degradation is believed to pro-
vide the principal mechanism for postpartum uterine
contraction. Consistent with this notion, the ability of
MMP-7 to hydrolyze a broad range of ECM substrates
(Rudolph-Owen et al. 1997), renders likely the possibil-
ity that its mislocalization in, or inappropriate release
from, epithelial and smooth muscle cells lacking
CD44HSPG augments ECM degradation and accelerates
the involution process. Thus, at the very least,
CD44HSPG-mediated docking of MMP-7 may help con-
trol physiological reproductive tissue remodeling and
prevent inappropriate ECM degradation.
It is noteworthy that MMP-7 null mice do not display
premature lactating mammary gland involution (Ru-
dolph-Owen et al. 1997), which might be expected if HB-
EGF provides an essential lactating mammary epithelial
cell survival signal and if processing of its precursor is
under the exclusive control of MMP-7. However, loss of
MMP-7 expression is accompanied by a several fold in-
crease in the expression of other MMPs, including
MMP-3 (Rudolph-Owen et al. 1997), which processes
proHB-EGF. It is therefore conceivable that MMP-3, or
possibly other metalloproteinases, compensate for the
loss of MMP-7-mediated proHB-EGF processing in these
mice.
Recent work by others provides support for the notion
that the CD44HSPG/MMP-7/HB-EGF/ErbB4 complex
may participate in maintaining the lactating mammary
gland phenotype. MMP-7 is expressed in the epithelium
of exocrine glands and its broad substrate specificity has
been proposed to help regulate exocrine duct patency
(Saarialho-Kere et al. 1995). ErbB4 is also expressed in
mammary gland epithelium, and appears to play a
prominent role in mammary gland differentiation and
maintenance (Jones et al. 1999). Although highly ex-
pressed throughout pregnancy, ErbB4 tyrosine phos-
phorylation is first detected in late pregnancy, when ep-
ithelial differentiation and secretory activity predomi-
nate over proliferation, and peaks during lactation when
mammary epithelium undergoes terminal differentia-
tion (Jones et al. 1999). Expression of a dominant nega-
tive ErbB4 was observed to result in premature lobuloal-
veolar condensation in midlactation (Jones et al. 1999).
The mammary gland phenotype in transgenic mice ex-
pressing a dominant negative ErbB4 is reminiscent of
that observed in the CD44−/− animals in the present
study, although it appears only in midlactation. The ear-
lier appearance of lobuloalveolar condensation in
CD44−/− animals may reflect increased proteolytic deg-
radation of ECM by mislocalized MMP-7, or possibly,
the loss of a CD44 function that is unrelated to the com-
plex. However, our observations, combined with the no-
tion that HB-EGF promotes cell survival in other situa-
tions (Opanashuk et al. 1999), are consistent with the
possibility that ErbB4 engagement by mature HB-EGF
may be implicated in protecting epithelial cells from
apoptosis during tissue remodeling. Integrin-mediated
epithelial survival signals, generated by engagement of
CD44-mediated assembly of MMP-7, HB-EGF, and ErbB4
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basement membrane ligands, may be impaired as a result
of ECM disruption that accompanies tissue remodeling,
and epithelial cells may temporarily require alternative
signals to ensure protection from anoikis (Frisch and
Ruoslahti 1997). One conceivable function of the com-
plex assembled by CD44HSPG may be to generate such
signals.
The present study supports the emerging view that
cell surface docking of secreted MMPs by adhesion re-
ceptors may regulate not only ECM degradation, but
growth factor activity as well (Brooks et al. 1996; Chen
1996; Murphy and Gavrilovic 1999; Bergers and Cous-
sens 2000; Yu and Stamenkovic 2000), and suggests that
localization may play a critical role in determining the
effect of MMP proteolytic activity on pathophysiological
processes. Our observations have also helped highlight
two hitherto unrecognized physiological functions of
CD44. The first is the ability of CD44HSPG to provide a
unique scaffold for the recruitment and functional coor-
dination of molecules that may play an important role in
tissue remodeling and maintenance. The second is par-
ticipation in the regulation of female reproductive organ
remodeling. Although these two functions may well be
related, further work will be required to determine the
degree to which the CD44HSPG-assembled complex is
implicated in the control of postpartum uterine involu-
tion and lactating mammary gland phenotype.
Materials and methods
Generation of CD44-deficient mice
The gene-targeting vector was constructed to delete sequences
within exons 4 and 5 of the murine CD44 gene that code for the
hyaluronan binding site (Peach et al. 1993). The murine DBA/l
lacJ genomic sequences used to produce the CD44 targeting
vector were amplified using long template PCR (Boerhinger-
Mannheim) with primers derived from the murine CD44 cDNA
sequences (Wolffe et al. 1994). The amplified genomic frag-
ments were subcloned and the sequence confirmed. The CD44
gene was targeted in DBA/l lacJ ES cells as described previously
(Roach et al. 1995), and DBA/l ES cells with the preplanned
CD44 mutation were identified by Southern analysis. Chimeric
offspring were produced after microinjection of DBA/l ES cells
into C57/Bl6 blastocysts. Germ-line transmission of the tar-
geted ES cells and identification of CD44−/− offspring on the
inbred DBA/l background has been described previously (Roach
et al. 1995).
Tissue specimens
Samples of female wild-type and CD44−/− DBA/1 mouse uterus
and mammary gland at various time points postpartum were
rapidly dissected, washed with cold PBS, embedded in OCT,
frozen in an isobutanol bath in liquid nitrogen, and stored at
−80°C until further processing. Sections 5 µm thick were cut in
a cryostat, mounted onto slides, air-dried at 4°C, and rinsed
twice with 90% ethanol followed by PBS to remove the OCT.
The sections were then fixed in 100% methanol for 20 min,
washed in PBS, and subjected to antibody staining.
Tissue staining and confocal microscopy
Tissue sections were blocked with PBS/10% serum (Jackson
Laboratory) derived from the same animal species as the sec-
ondary antibody used, at room temperature for 40 min prior to
incubation with the primary antibodies. Primary antibodies in-
cluded: polyclonal rabbit anti-MMP-7 antibody RM7-C and
polyclonal rabbit anti-MMP-7 antibody RM7-N for rat
proMMP-7 (Yu and Woessner 2000); anti-panCD44 mAb clone
241, and anti-CD44V3 mAb (R&D Systems); anti-pro-HB-EGF
C-18 antibody (Santa Cruz Biotechnology) for human samples
and anti-pro-HB-EGF M-18 antibody (Santa Cruz) for mouse
samples; anti-HB-EGF neutralizing antibody (R&D Systems);
monoclonal anti-ErbB4 Ab-4 (HFR-1), polyclonal rabbit anti-
ErbB4 Ab-2 (NeoMarkers), rat anti-human and mouse perlecan
antibody (Chemi-Con). Incubation with primary antibodies was
performed overnight at 4°C. The sections were then washed in
PBS, incubated with secondary fluorescein- or Texas Red-con-
jugated polyclonal anti-rabbit IgG or anti-mouse IgM or IgG
(Jackson Immunoresearch Laboratories) at room temperature
for 45 min, washed, and analyzed by confocal microscopy (in-
verted Zeiss LSM 510). Images were captured at 0.6 nm incre-
ments along the z axis and converted to composite images by
ImageSpace 3.10 software (Molecular Dynamics). Staining of
cells was performed prior to (surface staining) or following (in-
tracellular staining) fixation in 4% paraformaldehyde for 10 min
at room temperature. Cells were then mounted onto cover slips
and examined by confocal microscopy.
Expression constructs
The cDNA constructs used in these experiments were derived
from those described previously (Stamenkovic et al. 1991; Ben-
nett et al. 1995; unpublished reagents). All of the CD44 cDNAs,
including CD44H, CD44v6-10, CD44v7-10, CD44v3, 8-10 and
CD44v3-10 were subcloned into the pcDNA6His-v5 expression
vector (Invitrogen). HumanMMP-7 cDNAwas amplified from a
human colorectal carcinoma HT29 cell line cDNA expression
library by PCR using synthetic oligonucleotide primers comple-
mentary to the 5 and 3 extremities of the coding sequence. The
amplicons were inserted into pEF6V5Hisvectors (Invitrogen). E.
coli-derived recombinant human active MMP-7 was expressed
in BL21(DE3) cells using the PET3a vector (Yu and Woessner
2000) and recombinant pro-MMP-7 containing the E219Q mu-
tation was prepared by site-directed mutagenesis, as described
previously (Yu and Woessner 2000). Recombinant MMP-
7E219Q lacking the propeptide, prepared in E. coli, was a gift
from Dr. David Auld. Full-length TIMP-3 was prepared from the
conditioned medium of TIMP-3 PUNT-BHK cells.
Cell lines and cell culture
SH-SY5Y and Namalwa cells were maintained in RPMI me-
dium and CHO cells in DMEM, supplemented with 10% heat-
inactivated fetal bovine serum (FBS, Irvine Scientific) and 1%
penicillin and streptomycin. Namalwa cells were transfected
with CD44 constructs by electroporation (400V, 960 uF), and
transfectants were selected for resistance to G418 (GIBCO BRL)
at a concentration of 1.0 mg/mL.
Substrate zymography
Bovine carboxy-methylated-transferrin substrate was prepared
as described (Yu and Woessner 2000). Pig gelatin type A (Sigma,
0.5 mg/mL) was embedded in 7.5% SDS–polyacrylamide gels
and CM-transferrin (0.3 mg/mL) in 12.5% gels. Samples were
subjected to electrophoresis. Gels were washed with buffer con-
taining 2.5% Triton X-100, 50 mM Tris (pH 7.5) at 4°C to re-
move SDS, and then with buffer supplemented with 5 mM
CaCl2. Gels were then washed with incubation buffer (50 mM
Yu et al.
320 GENES & DEVELOPMENT
Tris at pH 7.5, 5 mM CaCl2) and incubated in the same buffer
with protease inhibitors (50 mM each of ZPCK, TPCK, TLCK,
and 4-(2-aminoethyl)-benzenesulfonyl chloride (Calbiochem)
for 18 h at 37°C. Gels were stained with 0.1% Coomassie Blue
in 40% MeOH, 10% acetic acid for 45 min, and destained with
7% acetic acid.
Tissue extracts
Samples (uteri and mammary glands) were collected 24–48 h
postpartum, washed with cold Ca++/Mg++-containing PBS,
minced, and polytron-homogenized in lysis buffer (see below) at
4°C. Homogenates were spun in a microfuge for 10 min, and the
soluble fraction was extracted, and subjected to immunopre-
cipitation with appropriate antibodies.
Immunoprecipitation and Western blot analysis
Immunoprecipitation and Western blot analysis were per-
formed according to standard procedures. Coimmunoprecipita-
tion of cell surface molecules was performed following prein-
cubation of the cells with the block solution containing 4% goat
serum, 50 µM zinc chloride, and protease inhibitors ZPCK,
PMSF, AEBSF, leupeptin, and phosphoramadon in PBS. Cells
were then incubated with the primary antibodies overnight at
4°C, in the same blocking solution, washed extensively with
PBS in the presence of 50 µM zinc chloride, and lysed with a
lysis buffer containing 1.25% Triton X-100 50 mMTris (pH 7.5),
0.15MNaCl, 10 mMCaCl2, 5 mMMgCl2, 50 µM ZnCl2, and 50
µM each of ZPCK, TPCK, TLCK, and 500 µM 4-(2-aminoethyl)-
benzenesulfonyl chloride (Calbiochem) and 1 µg/mL each of
aprotinin, leupeptin, and pepstatin (Sigma Co.). Lysates were
cleared for 15 min by centrifugation at 16,000 g at 4°C. Cell
surface complexes were immunoprecipitated by incubation
with Protein A+G agarose (Pierce Chemical Co.) beads at room
temperature for 45 min followed by centrifugation. Following
washes with 0.25% Triton X-100 50 mM Tris (pH 7.5), 0.15 M
NaCl, 10 mMCaCl2, 5 mMMgCl2, 50 µM ZnCl2 (Buffer W), the
samples were loaded in nonreducing SDS sample buffer, sub-
jected to electrophoresis, and transblotted onto 0.45 µm pore-
size nitrocellulose membrane. Antibodies used for Western blot
analysis of CD44, MMP-7, HB-EGF, and ErbB4 were anti-pan
CD44 clone 241 (Human), anti MMP-7 C-RM7, anti-pro-HB-
EGF (C-18), and anti erb-B4 Ab-4 HFR-1 (NeoMarkers), respec-
tively. For HB-EGF, an additional mAb that recognizes only the
fully processed, active form of HB-EGF and neutralizes its ac-
tivity (R&D systems) was used inWestern blot experiments. For
tubulin recognition, anti-tubulin antibody 4 (NeoMarkers) was
used. Immunoprecipitation of ErbB4 was performed using ErbB4
Ab-1 (NeoMarkers).
Pro-HB-EGF proteolytic cleavage with E. coli-derived purified
active MMP-7
After performing coimmunoprecipitation of CD44 and proHB-
EGF using, anti-panCD44 clone 241 mAb, the immunoprecipi-
tated complex was washed in a PBS buffer containing 25 mM
EDTA to deplete the endogenous MMP-7 from the complex,
followed by several washes with 0.25% Triton X-100 50 mM
Tris (pH 7.5), 0.15 M NaCl, 10 mM CaCl2, 5 mM MgCl2. Next
∼50 ng/mL of E. coli-derived purified active human MMP-7 was
added to the complex and incubated at 37°C overnight in the
presence or absence of MMP inhibitors SC44463 or BB94, fol-
lowed by Western blot analysis by using a mixture of anti-pro-
HB-EGF (C-18) antibody and anti-HB-EGF neutralizing mAb.
Apoptosis assays
Tunnel assays were performed on tissue sections and cells in
culture using the In Situ Cell Death Detection Kit (Boehringer
Mannheim) according to the manufacturer’s recommendations.
After 24 h culturing the cells in serum-free medium, Namalwa
transfectants were incubated without additional reagents or
with recombinant HB-EGF at 50 ng/mL, anti-HB-EGF neutral-
izing mAb 100 ng/mL, recombinant active MMP-7 at 100 ng/
mL, and recombinant proMMP-7E219Q at 300 ng/mL. The cells
were incubated in serum free culture medium supplemented or
not with the above reagents for another 24 h and assessed for
TUNEL positive staining by fluorescence microscopy.
Acknowledgments
We thank David Auld for the recombinant processed MMP-
7E219Q, Shuan-Su Yu for technical help, and Daniel Haber for
critical review of the manuscript and comments. This work was
supported by NIH grants CA55735 and GM48614 to I.S.
The publication costs of this article were defrayed in part by
payment of page charges. This article must therefore be hereby
marked “advertisement” in accordance with 18 USC section
1734 solely to indicate this fact.
References
Abramson, S.R. and Woessner, J.F.1994. Characterization of rat
matrilysin and its cDNA. Ann. New York Acad. Sci.
232: 362–364.
Aruffo, A., Stamenkovic, I., Melnick, M., Underhill, C.B., and
Seed, B. 1990. CD44 is the principal cell surface receptor for
hyaluronate. Cell 61: 1303–1313.
Bartolazzi, A., Jackson, D., Bennett, K., Aruffo, A., Dickinson,
R., Shields, J., Whittle, N., and Stamenkovic, I. 1995. Regu-
lation of growth and dissemination of human lymphoma by
CD44 splice variants. J. Cell Sci. 108: 1723–1733.
Bennett, K.L., Jackson, D.G., Simon, J.C., Tanczos, E., Peach, R.,
Modrell, B., Stamenkovic, I., Plowman, G., and Aruffo, A.
1995. CD44 isoforms containing exon V3 are responsible for
the presentation of heparin-binding growth factor. J. Cell
Biol. 128: 687–698.
Bergers, G. and Coussens, L.M. 2000. Extrinsic regulators of
epithelial tumor progression: Metalloproteinases. Curr.
Opin. Genet. and Dev. 10: 120–127.
Bode, W., Grams, F., Reinemer, P., Gomis-Ruth, F.X., Baumann,
U., McKay, D.B., and Stocker, W. 1996. The metzincin-su-
perfamily of zinc-peptidases. Adv. Exp. Med. Biol. 389: 1–11.
Brooks, P.C., Strömblad, S., Sanders, L.C., von Schalscha, T.K.,
Aimes, T.L., Stetler-Stevenson, W.G., Quigley, J.P., and
Cheresh, D.A. 1996. Localization of matrix metalloprotein-
ase MMP-2 to the surface of invasive cells by interaction
with integrin v 3. Cell 85: 683–693.
Butler, T.A., Zhu, C., Mueller, R.A., Fuller, G.C., Lemaire, W.J.
and Woessner, J.F. 1991. Inhibition of ovulation in the per-
fused rat ovary by the synthetic collagenase inhibitor SC
44463. Biol. Reprod. 44: 1183–1188.
Cha, J. and Auld, D.S. 1997. Site-directed mutagenesis of the
active site glutamate of human matrilysin: Investigation of
its role in catalysis. Biochemistry 36: 16019–16024.
Chen, W-T. 1996. Proteases associated with invadopodia, and
their role in degradation of extracellular matrix. Enzyme
Protein 49: 59–71.
Frisch, S.M. and Ruoslahti, E. 1997. Integrins and anoikis. Curr.
Opin. Cell Biol. 9: 701–706.
CD44-mediated assembly of MMP-7, HB-EGF, and ErbB4
GENES & DEVELOPMENT 321
Garcia, R.A.G., Vasudevan, K., and Buonanno, A. 1999. The
neuregulin receptor ErbB4 interacts with PDZ-containing
proteins at neuronal synapses. Proc. Natl. Acad. Sci.
97: 3596–3601.
Gechtman, Z., Alonso, J.L., Raab, G., Ingber, D.E., and Klags-
brun, M. 2000. The shedding of membrane-anchored hepa-
rin-binding epidermal-like growth factor is regulated by the
Raf/mitogen-activated protein kinase cascade and by cell ad-
hesion and spreading. J. Biol. Chem. 274: 28828–28835.
Higashiyama, S., Lau, K., Besner, G.E., Abraham, J.A., and
Klagsbrun, M. 1992. Structure of heparin-binding EGF-like
growth factor. J. Biol. Chem. 276: 6205–6212.
Higashiyama, S., Abraham, J.A., and Klagsbrun, M. 1993. Hep-
arin-binding EGF-like growth factor stimulation of smooth
muscle cell migration: Dependence on interactions with cell
surface heparan sulfate. J. Cell Biol. 122: 933–940.
Izumi, Y., Hirata, M., Hasuwa, H., Iwamoto, R., Umata, T.,
Miyado, K., Tamai, Y., Kurisaki, T., Sehara-Fujisawa, A.,
Ohno, S., and Mekada, E. 1998. A metalloproteinase-disin-
tegrin MDC9/meltrin-/ADAM 9 and PKC are involved in
TPA-induced ectodomain shedding of membrane-anchored
heparin binding-EGF-like growth factor. EMBO J. 17: 7260–
7272.
Jones, F.E., Welte, T., Fu, X-Y., and Stern, D.F. 1999. ErbB4
signaling in the mammary gland is required for lobuloalveo-
lar development and Stat5 activation during lactation. J. Cell
Biol. 147: 77–87.
Kaya, G., Rodriguez, I., Jorcano, L., Vassalli, P., and Stamen-
kovic, I. 1997. Selective suppression of CD44 in keratino-
cytes of mice bearing an antisense CD44 transgene driven by
a tissue-specific promoter disrupts hyaluronate metabolism
in the skin and impairs keratinocyte proliferation. Genes &
Dev. 11: 996–1007.
Lesley, J., Hyman, R., and Kincade, P.W. 1993. CD44 and its
interaction with extracellular matrix. Adv. Immunol.
54: 271–335.
Lukashev, M.E. and Werb, Z. 1998. ECM signaling: Orchestrat-
ing cell behavior and misbehavior. Trends Cell Biol. 8: 437–
441.
Marikovsky, M., Breuing, K., Liu, P.Y., Eriksson, E., Higashi-
yama, S., Farber, P., Abraham, J., and Klagsbrun, M. 1993.
Appearance of heparin-binding EGF-like growth factor in
wound fluid as a response to injury. Proc. Natl. Acad. Sci.
90: 3889–3893.
Murphy, G. and Gavrilovic, J. 1999. Proteolysis and cell migra-
tion: Creating a path? Curr. Opin. Cell Biol. 11: 614–621.
Nagase, H. and Woessner, J.F. 1999. Matrix metalloproteinases.
J. Biol. Chem. 274: 21491–21494.
Olayioye, M.A., Neve, R.M., Lane, H.A., and Hynes, N.E. 2000.
The ErbB signaling network: Receptor heterodimerization in
development and cancer. EMBO J. 19: 3159–3167.
Opanashuk, L.A., Mark, R.J., Porter, J., Damm, D., Mattson,
M.P., and Seroogy, K.B. 1999. Heparin-binding epidermal
growth factor-like growth factor in hippocampus: Modula-
tion of expression by seizures and anti-excitotoxic action. J.
Neurosci. 19: 133–146.
Peach, R.J., Hollenbaugh, D., Stamenkovic, I., and Aruffo, A.
1993. Identification of hyaluronic acid binding sites in the
extracellular domains of CD44. J. Cell Biol. 122: 257–264.
Powell, U.C., Fingleton, B., Wilson, C.L., Boothby, M., and Ma-
trisian, L.M. 1999. The metalloproteinase matrilysin proteo-
lytically generates active soluble Fas ligand and potentiates
epithelial cell apoptosis. Curr. Biol. 9: 1441–1447.
Prenzel, N., Zwick, E., Daub, H., Leserer, M., Abraham, R.,
Wallasch, C., and Ullrich, A. 1999. EGF receptor transacti-
vation by G-protein-coupled receptors requires metallopro-
teinase cleavage of proHB-EGF. Nature 402: 884–888.
Raab, G., Kover, K., Paria, B.C., Dey, S.K., Ezzell, R.M., and
Klagsbrun, M. 1996. Mouse preimplantation blastocysts ad-
here to cells expressing the transmembrane form of heparin-
binding EGF-like growth factor. Development 122: 637–645.
Roach, M.L., Stock, J.L., Byrum, R., Koller, B.H., and McNeish,
J.D. 1995. A new embryonic stem cell line from DBA/llacJ
mice allows genetic modification in a murine model of hu-
man inflammation. Exp. Cell Res. 221: 520–525.
Roca, X., Mate, J.L., Ariza, A., Munoz-Marmol, A.M., von
Uexkull-Guldeband, C., Pellicer, I., Navas-Palacios, J.J., and
Isamat, M. 1998. CD44 isoform expression follows two al-
ternative splicing pathways in breast tissue. Am. J. Pathol.
153: 183–190.
Rudolph-Owen, L.A., Hulboy, D.L., Wilson, C.L., Mudgett, J.,
and Matrisian, L.M. 1997. Coordinate expression of matrix
metalloproteinase family members in the uterus of normal,
matrilysin-deficient and stromelysin-1-deficient mice. En-
docrinology 138: 4902–4911.
Rudolph-Owen, L.A., Chan, R., Muller, W.J., and Matrisian,
L.M. 1998. The matrix metalloproteinase matrilysin influ-
ences early-stage mammary tumorigenesis. Cancer Res.
58: 5500–5506.
Saarialho-Kere, U.K., Crouch, E.C. and Parks, W.C. 1995. Ma-
trix metalloproteinase matrilysin is constitutively expressed
in adult human exocrine epithelium. J. Invest. Dermatol.
105: 190–196.
Schneider, P., Holler, N., Bodmer, J.L., Hahne, M., Frei, K., Fon-
tana, A., and Tschopp, J. 1998. Conversion of membrane-
bound Fas(CD95) ligand to its soluble form is associated
with downregulation of its proapoptotic activity and loss of
liver toxicity. J. Exp. Med. 187: 1205–1213.
Screaton, G.R., Bell, M.V., Jackson, D.G., Cornelis, F.B., Gerth,
U., and Bell, J.I. 1992. Genomic structure of DNA encoding
the lymphocyte homing receptor CD44 reveals at least 12
alternatively spliced exons. Proc. Natl. Acad. Sci. 89: 12160–
12164.
Sellers, A. and Woessner, J.F. 1980. The extraction of a neutral
metalloproteinase from the involuting rat uterus, and its ac-
tion on cartilage proteoglycan. Biochem. J. 189: 521–531.
Shapiro, S.D. 1998. Matrix metalloproteinase degradation of ex-
tracellular matrix: Biological consequences.Curr. Opin. Cell
Biol. 10: 602–608.
Sherman, L., Wainwright, D., Ponta, H., and Herrlich, P. 1998.
A splice variant of CD44 expressed in the apical ectodermal
ridge presents FGF-8 to limbmesenchyme and is required for
limb outgrowth. Genes & Dev. 12: 1058–1071.
Stamenkovic, I., Aruffo, A., Amiot, M., and Seed, B. 1991. The
hematopoietic and epithelial forms of CD44 are distinct
polypeptides with different adhesion potentials for hyaluro-
nate-bearing cells. EMBO J. 10: 343–348.
Suzuki, M., Raab, G., Moses, M.A., Fernandez, C.A., and Klags-
brun, M. 1997. Matrix metalloproteinase-3 releases active
heparin-binding EGF-like growth factor by cleavage at a spe-
cific juxtamembrane site. J. Biol. Chem. 272: 31730–31737.
Sweeney, C., Lai, C., Riese II, D.J., Diamonti, A.J., Cantley, L.C.,
and Carraway, K.L. 2000. Ligand discrimination in signaling
through ErbB4 receptor homodimer. J. Biol. Chem.
275: 19803–19807.
Sy, M.S., Guo, Y.J., and Stamenkovic, I. 1991. Distinct effects of
two CD44 isoforms on tumor growth in vivo. J. Exp. Med.
174: 859–866.
Vu, T.H. and Werb, Z. 2000. Matrix metalloproteinases: Effec-
tors of development and normal physiology. Genes & Dev.
14: 2123–2133.
Werb, Z. 1997. ECM and cell surface proteolysis: Regulating
Yu et al.
322 GENES & DEVELOPMENT
cellular ecology. Cell 91: 439–442.
Wilson, C.L. and Matrisian, L.M. 1996. Matrilysin: An epithe-
lial matrix metalloproteinase with potentially novel func-
tions. Int. J. Biochem. Cell Biol. 28: 123–136.
Wilson, C.L., Heppner, K.J., Rudolph, L.A., and Matrisian, L.M.
1995. The metalloproteinase matrilysin is preferentially ex-
pressed by epithelial cells in a tissue-restricted pattern in the
mouse. Mol. Biol. Cell 6: 851–869.
Wilson, C.L., Heppner, K.J., Labosky, P.A., Hogan, B.L., and Ma-
trisian, L.M. 1997. Intestinal tumorigenesis is suppressed in
mice lacking the metalloproteinase matrilysin. Proc. Natl.
Acad. Sci. 94: 1402–1407.
Wilson, C.L., Ouillette, A.J., Satchell, D.P., Ayabe, T., Lopez-
Boado, Y.S., Stratman, J.L., Hultgren, S.J., Matrisian, L.M.,
and Parks, W.C. 1999. Regulation of intestinal -defensin
activation by the metalloproteinase matrilysin in innate
host defense. Science 286: 113–117.
Witty, J.P., McDonnell, S., Newell, K., Cannon, P., Navre, M.,
Tressler, R., and Matrisian, L.M. 1994. Modulation of mat-
rilysin levels in colon carcinoma cell lines affects tumorige-
nicity in vivo. Cancer Res. 54: 4805–4812.
Woessner, J.F. 1996. Regulation of matrilysin in the rat uterus.
Biochem. Cell Biol. 74: 777–784.
Woessner, J.F. and Taplin, C.J. 1988. Purification and properties
of a small latent matrix metalloproteinase of the rat uterus.
J. Biol. Chem. 263: 16918–16925.
Wolffe, E.J., Gause, W.C., Pelfrey, C.M., Holland, S.M., Stein-
berg, A.D., and August, J.T. 1994. The cDNA sequence of
mouse Pgp-1 and homology to human CD44 cell surface
antigen and proteoglycan core/link proteins. J. Biol. Chem.
265: 341–347.
Yu, Q. and Stamenkovic, I. 2000. Cell surface-localized matrix
metalloproteinase-9 proteolytically activates TGF- and
promotes tumor invasion and angiogenesis. Genes & Dev.
14: 63–176.
Yu, W-H. and Woessner, J.F., Jr. 2000. Heparan sulfate proteo-
glycans as extracellular docking molecules for matrilysin
(Matrix metalloproteinase 7). J. Biol. Chem. 275: 4183–4191.
CD44-mediated assembly of MMP-7, HB-EGF, and ErbB4
GENES & DEVELOPMENT 323
